financial summary for Lupin Ltd

• Consolidated revenue for Q1 FY26 stood at ₹6,268 crore, up 11.9 percent year-on-year. • EBITDA came in at ₹1,806.3 crore, reflecting a 38 percent YoY increase. EBITDA margin improved to 29.3 percent from 23.7 percent. • Profit Before Tax (PBT) was ₹1,415.5 crore, up 42.6 percent YoY. • Net Profit (PAT) surged to ₹1,221 crore, registering 51.4 percent growth compared to last year. • Earnings Per Share (EPS) for the quarter stood at ₹26.69, up 51.8 percent YoY. • Gross profit was ₹4,391.9 crore with a gross margin of 71.3 percent. • Revenue by geography: • US: ₹2,404 crore, up 24.3 percent, contributing 39 percent of total sales • India: ₹2,089 crore, up 7.8 percent, contributing 34 percent • Other developed markets: ₹775 crore, up 17.4 percent • Emerging markets: ₹652 crore, up 5.2 percent • The Active Pharmaceutical Ingredient (API) segment declined by 33 percent, with sales at ₹243 crore. • Personnel cost stood at ₹1,083 crore, about 17.6 percent of sales. • Manufacturing and other expenses were ₹1,772 crore, around 28.7 percent of sales. • R&D investment was ₹484 crore, forming 7.9 percent of revenue. • The company moved from net debt to a net cash position, with ₹1,238.6 crore in cash surplus. • For Q4 FY25, revenue was ₹5,667 crore and net profit was ₹782 crore, up 112 percent YoY. • FY25 full-year revenue was ₹22,192 crore, up 12.9 percent, with net profit at ₹3,306 crore, up 70.8 percent. • Full-year EBITDA margin for FY25 was 24.7 percent, improved by 469 basis points YoY. • Trailing P/E ratio as of mid-2025 is around 27.6. • From FY25 data: • Basic EPS: ₹51.10 • Net profit margin: 15.85 percent • Return on Equity: 11.29 percent • Price-to-Book ratio: 3.58 • EV to EBITDA: 20.6 times • Debt-to-equity ratio: 0.00 • Current ratio: 2.51 • Quick ratio: 1.71